06 Dec Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies
Hummingbird Bioscience and Cancer Research UK today announced that the first patient has been dosed in a Phase 1 clinical trial of HMBD-001 for the treatment of patients with advanced HER3-expressing solid malignancies (NCT05057013)....